大行评级丨高盛：上调Agios Pharmaceuticals目标价至28美元，维持“中性”评级

Group 1 - Goldman Sachs raised the 12-month target price for Agios Pharmaceuticals from $25 to $28 while maintaining a "Neutral" rating [1] - The firm believes that Agios will realize its first wave of value through the U.S. launch of Aqvesme in the short term [1] - In the medium term, the focus will be on when the prescription revenue mismatch will converge [1] - The long-term outlook depends on whether Agios can achieve further success in the sickle cell disease indication [1]